Stock Earnings

Question 1

SAB Biotherapeutics Inc'in temel mali tabloları nelerdir?

Accepted Answer

Son mali tabloya (Form-10K) göre, SAB Biotherapeutics Inc'in toplam varlıkları $44 olup, net loss $-34'dir.

Question 2

SABS'ün temel finansal oranları nelerdir?

Accepted Answer

SAB Biotherapeutics Inc'in cari oranı 2.44, net kâr marjı -3,400, hisse başına satış $0.1'dir.

Question 3

SAB Biotherapeutics Inc'in geliri segment veya coğrafya bazında nasıl dağılıyor?

Accepted Answer

SAB Biotherapeutics Inc largest revenue segment is Immunotheraphies, at a revenue of 2,238,991 in the most earnings release.For geography, United States is the primary market for SAB Biotherapeutics Inc, at a revenue of 2,238,991.

Question 4

SAB Biotherapeutics Inc kârlı mı?

Accepted Answer

no, son mali tablolara göre SAB Biotherapeutics Inc'in net loss $-34'dir.

Question 5

SAB Biotherapeutics Inc'in herhangi bir yükümlülüğü var mı?

Accepted Answer

yes, SAB Biotherapeutics Inc'in yükümlülüğü 18'dir.

Question 6

SAB Biotherapeutics Inc'in tedavüldeki hisse sayısı kaçtır?

Accepted Answer

SAB Biotherapeutics Inc'in toplam tedavüldeki hisse sayısı 9.28'dir.

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	0	1	2	23	60	55
Revenue Growth (YoY)	-100%	-50%	-91%	-62%	9%	--
Cost of Revenue	--	--	--	--	--	--
Gross Profit	--	--	--	--	--	--
Selling, General & Admin	11	13	23	16	17	6
Research & Development	29	29	16	36	57	27
Operating Expenses	41	44	40	52	74	34
Other Non Operating Income (Expenses)	4	7	-4	10	-4	0
Pretax Income	-37	-34	-42	-18	-17	20
Income Tax Expense	--	0	0	0	--	--
Net Income	-37	-34	-42	-18	-17	20
Net Income Growth	-8%	-19%	133%	6%	-185%	--
Shares Outstanding (Diluted)	9.29	9.26	5.52	4.35	4.29	2.7
Shares Change (YoY)	0%	68%	27%	1%	59%	--
EPS (Diluted)	-3.99	-3.68	-7.64	-4.31	-3.99	7.45
EPS Growth	-8%	-52%	77%	8%	-154%	--
Free Cash Flow	-30	-34	-25	-25	-8	-2
Free Cash Flow Per Share	-3.22	-3.67	-4.52	-5.74	-1.86	-0.74
Gross Margin	--	--	--	--	--	--
Operating Margin	0%	-4,200%	-1,850%	-121.73%	-21.66%	36.36%
Profit Margin	0%	-3,400%	-2,100%	-78.26%	-28.33%	36.36%
Free Cash Flow Margin	0%	-3,400%	-1,250%	-108.69%	-13.33%	-3.63%
EBITDA	-41	-41	-37	-28	-12	20
EBITDA Margin	0%	-4,100%	-1,850%	-121.73%	-20%	36.36%
D&A For EBITDA	0	1	0	0	1	0
EBIT	-41	-42	-37	-28	-13	20
EBIT Margin	0%	-4,200%	-1,850%	-121.73%	-21.66%	36.36%
Effective Tax Rate	--	0%	0%	0%	--	--

SAB Biotherapeutics Inc (SABS) Price

SABS Stock Price Chart

SABS Income

Follow-Up Questions